R&D at the heart of European Union's plans for economic recovery, says Spanish minister

29 January 2010

Speaking before the European Parliament yesterday, Spain's Minister for Science and Innovation, Cristina Garmendia, says that she supports putting R&D at the heart of the European Union as a key to economic recovery.

As part of the EU Presidency, held by Spain for the first half of 2010, the country's science minister appeared before the Committee on Industry, Research and Energy (ITRE) of the European Parliament in Brussels, where she set out her department's top priorities. Ms Garmendia said the Spanish Presidency of the EU would work to ensure that R&D initiatives in Europe are better able to respond to major challenges such as new energy sources, climate change, health, ageing, and particularly economic recovery and growth.

By doing this, she stated, Spain will clearly promote 'the role of science in dealing with our most visible challenges and daily concerns, and in economic recovery and growth. Without more science and more innovation - and above all the necessary interaction between them - Europe will not be able to maintain its current leadership, much less aspire to improving its position in the international arena.'

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Pharmaceutical